The purpose of this study is to demonstrate whether subjects respond similarly to the Onset of Effect Questionnaire (OEQ) administered pre-dose versus post-dose, while receiving SYMBICORT® pMDI 80/4.5 μg x 2 actuations twice daily or budesonide HFA pMDI 80 μg x 2 actuations twice daily.

Inclusion Criteria:

• Male or Female, > 18 years of age
• Mild to moderate asthma requiring treatment with an inhaled corticosteroid
• Diagnosis of asthma for at least 6 months

Exclusion Criteria:

• Subjects requiring treatment with systemic corticosteroids (e.g., oral, parenteral, ocular)
• Subjects with severe asthma, as judged by investigator
• Any significant disease or disorder that may jeopardize a subject's safety